BioStock: BioInvent secures FDA Fast Track Designation for BI-1808

BioInvent has published its Q1 2025 interim report, outlining progress in its clinical programmes. Adding to the momentum, the FDA has granted Fast Track Designation to BI-1808 for the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, subtypes of cutaneous T-cell lymphoma. We reached out to BioInvent’s CEO, Martin Welschof, for a comment.

Read the interview at biostock.se:

https://www.biostock.se/en/2025/05/bioinvent-secures-fda-fast-track-designation-for-bi-1808/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/